Maravai LifeSciences Holdings Inc. Class A Common Stock vs Suncor Energy Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Suncor Energy Inc. trades at $75.94 (market cap $87.48B). The key difference: Suncor Energy Inc. is far larger — about 89.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Suncor Energy Inc. pays a 2.26% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Suncor Energy Inc. for 57 Days on average.
| MRVI | SU | |
|---|---|---|
Market Cap | $972.90M | $87.48B |
Volume | 4,325,710 | 3,692,639 |
Sector | Health | Energy |
52-Week High | $9.00 | $75.89 |
52-Week Low | $2.83 | $38.17 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $1.08B | $94.00B |
Dividend Yield | — | 2.26% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Suncor Energy (SU) trades at $75.89, up 3.24% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 14.32, net income margin of 14.7%, and consistent cash flow generation. Recent news highlights strategic asset divestitures and leadership transitions, while analyst consensus remains strongly positive with 74% buy ratings.
Outlook remains favorable given SU's integrated oil sands operations and aggressive shareholder returns through dividends and buybacks. Key risks include commodity price volatility and operational challenges, but the company's strong balance sheet and improving debt metrics provide stability. Current valuation appears reasonable relative to earnings potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →